D.O.R.C. Dutch Ophthalmic Research Center (International) B.V.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
D.O.R.C. Dutch Ophthalmic Research Center (International) B.V. - overview
Established
1983
Location
-, -, Netherlands
Primary Industry
Medical Devices & Equipment
About
D. O. R. C.
is a Netherlands-based company specializing in innovative ophthalmic surgical products and services, focused on enhancing surgical precision and patient outcomes in cataract and vitreoretinal procedures. D. O. R.
C. Dutch Ophthalmic Research Center (International) B. V. was founded in 1983 in the Netherlands.
The company is known for its advanced ophthalmic surgical solutions, catering to healthcare professionals worldwide. The firm has completed 5 deals since inception, with the most recent deal occurring on December 15, 2023, when Carl Zeiss Meditec AG acquired D. O. R.
C. for EUR 985 million, enhancing its ophthalmic product offerings. Pierre Billardon serves as the CEO of the company. D.
O. R. C. specializes in providing a comprehensive range of products and services for ophthalmic surgery, focusing on innovation and sustainability.
Core offerings include the EVA NEXUS™ platform, featuring advanced surgical instruments, liquids, and tamponades for cataract and vitreoretinal procedures. VisionBlue® anterior stain has been used in over 10 million cataract procedures since its launch. The portfolio also includes the DMEK Disposable Surgical Set and a variety of corneal instruments designed to meet diverse surgical needs. D.
O. R. C. serves healthcare professionals globally, with clients that include hospitals, surgical centers, and ophthalmic specialists across Europe, North America, and Asia.
In 2022, D. O. R. C.
reported a revenue of EUR 175,069,718. 20 and an EBITDA of EUR 40,736,703. 90. The company generates revenue through direct sales of its specialized ophthalmic surgical products to healthcare providers, primarily operating on a B2B model.
Sales typically involve substantial orders for flagship products, ensuring accessibility for healthcare facilities while maintaining a commitment to sustainability and innovation. D. O. R.
C. plans to leverage its recent acquisition by Carl Zeiss Meditec AG to expand its product offerings and enhance market presence. The acquisition, finalized on December 15, 2023, will enable D. O.
R. C. to integrate with ZEISS Medical Technology’s broad ophthalmic portfolio. This strategic move is aimed at enhancing D.
O. R. C. ’s capabilities in innovative surgical solutions, thereby fostering growth in existing markets and exploring new regions.
Current Investors
Eurazeo
Primary Industry
Medical Devices & Equipment
Sub Industries
Optometrists & Opticians Products and Services, Medical Supplies
Website
www.dorc.eu
Company Stage
Mature
Total Amount Raised
Subscriber access only
D.O.R.C. Dutch Ophthalmic Research Center (International) B.V. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Trade Sale | Completed | D.O.R.C. Dutch Ophthalmic Research Center (International) B.V. | - | ||||||||
| Add-on | Completed | WEFIS GmbH | - | ||||||||
| Add-on | Completed | WEFIS GmbH | - | ||||||||
| Secondary Buyout | Completed | D.O.R.C. Dutch Ophthalmic Research Center (International) B.V. | - | ||||||||
| Private Debt | Completed | D.O.R.C. Dutch Ophthalmic Research Center (International) B.V. | - |
Displaying 1 - 5 of 7
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.